ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,602Medicare Part D Prescriptions Filled, Including Refills

Rank: 333 out of 1844

$484K Total Retail Price of All Prescriptions

Rank: 383 out of 1844

426 Patients Receiving at Least One Drug in Part D
93%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 426 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

15% of this provider’s 426 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 7,788 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

21% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$56 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
LEVOTHYROXINE SODIUM 348 337 1 1
FUROSEMIDE 305 269 2 7
AMLODIPINE BESYLATE 276 254 3 6
SIMVASTATIN 269 261 4 3
HYDROCODONE-ACETAMINOPHEN 259 218 S3 5 2
METOPROLOL TARTRATE 183 178 6 11
SERTRALINE HCL 168 168 7 21
POTASSIUM CHLORIDE 164 162 8 16
HYDROCHLOROTHIAZIDE 157 154 9 9
TAMSULOSIN HCL 155 134 10 27
METFORMIN HCL 145 143 11 8
OMEPRAZOLE 144 139 12 5
LISINOPRIL 143 137 13 4
ALENDRONATE SODIUM 138 124 14 25
GLIMEPIRIDE 133 130 15 35
DIGOXIN 128 115 16 67
ZOLPIDEM TARTRATE 117 117 17 23
DONEPEZIL HCL 115 115 18 26
ATORVASTATIN CALCIUM 113 99 19 12
WARFARIN SODIUM 112 80 20 13
CEPHALEXIN 106 100 21 56
MELOXICAM 98 86 22 28
METOPROLOL SUCCINATE 90 90 23 14
ENALAPRIL MALEATE 90 90 23 69
NAMENDA 87 87 25 33
GABAPENTIN 81 69 26 15
PREDNISONE 79 77 27 40
LOSARTAN POTASSIUM 65 65 28 24
LISINOPRIL-HYDROCHLOROTHIAZIDE 65 65 28 20
SPIRIVA 64 48 30 57
PANTOPRAZOLE SODIUM 62 62 31 32
SPIRONOLACTONE 59 56 32 60
PAROXETINE HCL 59 56 32 68
AZITHROMYCIN 58 51 34 37
BENAZEPRIL-HYDROCHLOROTHIAZIDE 57 48 35 225
TRAMADOL HCL 54 52 36 18
CARVEDILOL 54 38 36 22
NABUMETONE 54 54 36 158
ALLOPURINOL 52 47 39 29
ADVAIR DISKUS 51 32 40 51
CIPROFLOXACIN HCL 50 49 41 62
PLAVIX 50 50 41 61
CRESTOR 50 50 41 30
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 20, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.